Chemomab Therapeutics Ltd. (CMMB) stock
CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.53+0.13 (+9.29%)
Close on Nov 13, 2026Market cap $11.00MP/E 1.1Yield –
Chemomab Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Chemomab Therapeutics's EPS for the twelve months ending Jun 30, 2023 was $0.07, up 69.0% year over year. For fiscal 2025 it was $0.02, down 53.8% from the year before. The highest annual figure on record is $0.31 in fiscal 2017.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0.02 | -53.8% |
| FY2024 | Dec 31, 2024 | $0.04 | -62.1% |
| FY2023 | Dec 31, 2023 | $0.10 | -14.9% |
| FY2022 | Dec 31, 2022 | $0.12 | +101.7% |
| FY2021 | Dec 31, 2021 | $0.06 | +36.4% |
| FY2020 | Dec 31, 2020 | $0.04 | -80.5% |
| FY2019 | Dec 31, 2019 | $0.23 | -27.5% |
| FY2018 | Dec 31, 2018 | $0.31 | 0.0% |
| FY2017 | Dec 31, 2017 | $0.31 | +25.3% |
| FY2016 | Dec 31, 2016 | $0.25 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0.00 | -92.5% |
| Q2 FY2025 | Jun 30, 2025 | $0.00 | – |
| Q2 FY2024 | Jun 30, 2024 | $0.01 | -62.9% |
| Q2 FY2023 | Jun 30, 2023 | $0.04 | +33.3% |
| Q1 FY2023 | Mar 31, 2023 | $0.04 | +81.8% |
| Q4 FY2022 | Dec 31, 2022 | -$0.04 | – |
| Q3 FY2022 | Sep 30, 2022 | $0.04 | +169.2% |
| Q2 FY2022 | Jun 30, 2022 | $0.03 | +107.7% |
| Q1 FY2022 | Mar 31, 2022 | $0.02 | +100.0% |
| Q4 FY2021 | Dec 31, 2021 | -$0.02 | – |
| Q3 FY2021 | Sep 30, 2021 | $0.01 | +44.4% |
| Q2 FY2021 | Jun 30, 2021 | $0.01 | +62.5% |
| Q1 FY2021 | Mar 31, 2021 | $0.01 | -15.4% |
| Q4 FY2020 | Dec 31, 2020 | -$0.01 | – |
| Q3 FY2020 | Sep 30, 2020 | $0.01 | – |
| Q2 FY2020 | Jun 30, 2020 | $0.01 | – |
| Q1 FY2020 | Mar 31, 2020 | $0.01 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.05 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.03 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.11 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?